[Federal Register Volume 75, Number 169 (Wednesday, September 1, 2010)]
[Notices]
[Page 53720]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-21785]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal
Regulations (CFR), this is notice that on May 5, 2010, Austin Pharma
LLC., 811 Paloma Drive, Suite C, Round Rock, Texas 78665-2402, made
application by renewal to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of the basic classes of controlled
substances listed in schedules I and II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Marihuana (7360)........................... I
Tetrahydrocannabinols (7370)............... I
Alphamethadol (9605)....................... I
Nabilone (7379)............................ II
Methadone (9250)........................... II
Methadone Intermediate (9254).............. II
Levo-alphacetylmethadol (9648)............. II
Alfentanil (9737).......................... II
Remifentanil (9739)........................ II
Sufentanil (9740).......................... II
Fentanyl (9801)............................ II
------------------------------------------------------------------------
The company plans to manufacture the listed controlled substances
in bulk for distribution to its customers.
In reference to drug code 7360 (Marihuana), the company plans to
bulk manufacture cannabidiol as a synthetic intermediate. This
controlled substance will be further synthesized to bulk manufacture a
synthetic THC (7370). No other activity for this drug code is
authorized for this registration.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than November 1, 2010.
Dated: August 2, 2010.
Joseph T. Rannazzisi,
Deputy Assistant Administrator/Deputy Chief of Operation, Office of
Diversion Control, Drug Enforcement Administration.
[FR Doc. 2010-21785 Filed 8-31-10; 8:45 am]
BILLING CODE 4410-09-P